Most HPV infections clear on their own without any treatment. Roughly 80% of infections are transient and resolve spontaneously within two years. The remaining 20% that persist are where the real risks begin, potentially leading to genital warts, precancerous cell changes, or, over a decade or more, cancer.
What happens in your specific case depends on whether you’re dealing with a low-risk strain (the kind that causes warts) or a high-risk strain (the kind linked to cancer), how long the infection persists, and how well your immune system responds.
Most Infections Clear Without Treatment
HPV is extremely common, and your immune system is usually capable of suppressing the virus on its own. In one longitudinal study tracking patients over 12 months, about 62% had cleared their HPV infection by that point. By 24 months, roughly 80% of all infections have resolved. During this window, the virus is present in your body but often causes no symptoms and no lasting damage.
The infections that don’t clear within that timeframe are considered persistent. Persistent infection with a high-risk HPV type is the single most important risk factor for developing cancer later on. Two strains in particular, HPV 16 and HPV 18, together account for about 66% of all cervical cancers worldwide. HPV 16 alone is responsible for roughly half.
What Happens With Low-Risk Strains
Low-risk HPV types, primarily strains 6 and 11, cause about 90% of anogenital warts. These strains are not linked to cancer. If genital warts are left alone, they can go one of three directions: resolve on their own, stay the same, or grow in size and number. There’s no way to predict which path yours will take.
Warts that grow can become physically uncomfortable, cause itching or irritation, and make sexual activity painful or distressing. In rare cases, HPV types 6 and 11 can also cause warts in the mouth, nose, or throat. During pregnancy, an untreated infection can, in uncommon circumstances, lead to respiratory papillomatosis in infants, a condition where warts grow in a baby’s airway.
How High-Risk HPV Progresses to Cancer
When a high-risk HPV infection persists, it can cause cells to change gradually over years. In the cervix, these changes are classified into stages of abnormality. The progression is slow and follows a general pattern: normal cells develop mild changes, then moderate changes, then severe changes, and finally invasive cancer. This entire process typically takes 10 to 15 years, which is why regular screening is so effective at catching problems early.
The moderate stage of cervical cell changes has been studied closely in women who were monitored without immediate treatment. Within two years, about 50% of these cases regressed to normal on their own. Around 32% stayed the same, and 18% progressed to a more severe stage. For women under 30, the odds were even more favorable: 60% regressed and only 11% progressed. Out of more than 3,000 women tracked in a large review, only 15 cases (0.5%) developed invasive cervical cancer during the monitoring period.
These numbers explain why younger women with moderate cell changes are sometimes offered active surveillance rather than immediate procedures. The body often corrects the problem without intervention. But the numbers also show that progression is real, and without monitoring, a slowly worsening case could go undetected until it becomes much harder to treat.
Cancers Linked to Persistent HPV
Cervical cancer gets the most attention, but persistent high-risk HPV can cause cancer in several parts of the body. Each year in the United States, HPV is estimated to cause about 37,800 cancers. The breakdown by site shows how wide-reaching this virus is:
- Anal cancer: Over 90% of cases are caused by HPV
- Vaginal cancer: About 75% of cases are HPV-related
- Oropharyngeal (throat) cancer: Around 70% of cases are linked to HPV
- Vulvar cancer: About 69% of cases involve HPV
- Penile cancer: Roughly 63% of cases are HPV-related
HPV-related throat cancer has been rising significantly in recent decades, particularly in men. This type develops in the back of the throat, the base of the tongue, or the tonsils, and is most commonly associated with HPV 16.
Risks for Men
About one in three men worldwide carry genital HPV at any given time. Most of these infections are asymptomatic, which means men often have no idea they’re infected. There is no approved routine HPV screening test for men the way there is for cervical screening, so persistent infections can go entirely undetected.
In men, untreated HPV most commonly shows up as genital warts. But high-risk strains can lead to penile, anal, and oropharyngeal cancers. The International Agency for Research on Cancer estimated about 69,400 cancer cases in men were caused by HPV in a single year globally. Men who have sex with men face a particularly elevated risk of anal HPV infection and anal cancer.
Why Some People Don’t Clear the Virus
The biggest factor determining whether HPV causes problems is whether your immune system can eliminate it. People with weakened immune systems, including those living with HIV, organ transplant recipients on immunosuppressive medications, or anyone on long-term immune-suppressing therapy, are far more likely to develop persistent infections that progress.
Smoking also plays a role. It reduces the immune system’s ability to fight HPV in cervical tissue specifically, making smokers more likely to develop persistent infections and precancerous changes. Having multiple HPV types simultaneously, or being infected with HPV 16 in particular, increases the risk that the infection will stick around.
How Screening Catches Problems Early
Because HPV-related cancers develop over such a long timeline, screening is one of the most effective tools for preventing them. Current guidelines recommend cervical screening starting at age 21. For people aged 30 to 65, the options include a primary HPV test every five years, a Pap test every three years, or both tests together every five years. Starting at age 25, primary HPV testing alone every five years is increasingly recommended based on its demonstrated accuracy.
These intervals exist because the progression from persistent infection to cancer is measured in years, not months. A five-year screening window is wide enough to catch precancerous changes well before they become dangerous. The key risk of leaving HPV “untreated” isn’t really about treating the virus itself, since there is no antiviral therapy for HPV. It’s about missing the window to detect and remove abnormal cells before they turn cancerous. Staying current on screening is what transforms HPV from a potential cancer risk into a manageable, highly preventable one.